Dialysability of sugammadex and its complex with rocuronium in intensive care patients with severe renal impairment

British Journal of Anaesthesia

Volumn 109, Issue 3, 2012, Pages 382-390

  Cammu, G ^a   Van Vlem, B ^a   Van Den Heuvel, M ^b   Stet, L ^c   El Galta, R ^d   Eloot, S ^a   Demeyer, I ^a  

^a OLV HOSPITAL   (Belgium)

^b Clinical PKPD   (Netherlands)

^c CNS Global Clinical Trial Management   (Netherlands)

^d MSD   (Netherlands)

Author keywords

kidney failure; neuromuscular block; renal dialysis; rocuronium; sugammadex

Indexed keywords

ADRENALIN; DOBUTAMINE; MIDAZOLAM; MORPHINE; NORADRENALIN; PROPOFOL; REMIFENTANIL; ROCURONIUM; SUFENTANIL; SUGAMMADEX;

ADULT; AGED; ARTICLE; BRONCHOSCOPY; CIRCULATION; CLINICAL ARTICLE; CREATININE CLEARANCE; DIALYSATE; DIALYSIS; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DIALYSABILITY; ENDOTRACHEAL TUBE; FEMALE; GENERAL ANESTHESIA; HAND EDEMA; HEART FAILURE; HEART OUTPUT; HEART SURGERY; HEMODIALYSIS; HUMAN; INTENSIVE CARE; KIDNEY DISEASE; MALE; PATIENT MONITORING; PLASMA CLEARANCE; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY FAILURE; SINGLE DRUG DOSE; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; VASCULAR SURGERY;

EID: 84865236740     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aes207     Document Type: Article

References (28)

1. Bom A, Hope F, Rutherford S, Thomson K. Preclinical pharmacology of sugammadex. J Crit Care 2009; 24: 29-35
2. Shields M, Giovannelli M, Mirakhur RK, Moppett I, Adams J, Hermens Y. Org 25969 (sugammadex), a selective relaxant binding agent for antagonism of prolonged rocuronium-induced neuromuscular block. Br J Anaesth 2006; 96: 36-43
3. Sacan O, White PF, Tufanogullari B, Klein K. Sugammadex reversal of rocuronium-induced neuromuscular blockade: A comparison with neostigmine-glycopyrrolate and edrophonium-atropine. Anesth Analg 2007; 104: 569-74
4. Suy K, Morias K, Cammu G, et al. Effective reversal of moderate rocuronium- or vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent. Anesthesiology 2007; 106: 283-8
5. Jones RK, Caldwell JE, Brull SJ, Soto RG. Reversal of profound rocuronium-induced blockade with sugammadex: A randomized comparison with neostigmine. Anesthesiology 2008; 109: 816-24
6. Blobner M, Eriksson LI, Scholz J, et al. Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: Results of a randomised, controlled trial. Eur J Anaesthesiol 2010; 27: 874-81
7. Khuenl-Brady KS, Wattwil M, Vanacker BF, Lora-Tamayo JI, Rietbergen H, Alvarez-Gómez JA. Sugammadex provides faster reversal of vecuronium-induced neuromuscular blockade compared with neostigmine: A multicenter, randomized, controlled trial. Anesth Analg 2010; 110: 64-73
8. Lemmens HJ, El-Orbany MI, Berry J, Morte JB Jr, Martin G. Reversal of profound vecuronium-induced neuromuscular block under sevoflurane anesthesia: Sugammadex versus neostigmine. BMC Anesthesiol 2010; 10: 15
9. Peeters PA, van den Heuvel MW, van Heumen E, et al. Safety, tolerability and pharmacokinetics of sugammadex using single high doses (up to 96 mg/kg) in healthy adult subjects: A randomized, double-blind, crossover, placebo-controlled, single-centre study. Clin Drug Investig 2010; 30: 867-74
10. Peeters PA, Passier P, Smeets J, et al. Sugammadex is cleared rapidly and primarily unchanged via renal excretion. Biopharm Drug Dispos 2011; 32: 159-67
11. Cooper RA, Maddineni VR, Mirakhur RK, et al. Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure. Br J Anaesth 1993; 71: 222-6
12. Robertson EN, Driessen JJ, Booij LH. Pharmacokinetics and pharmacodynamics of rocuronium in patients with and without renal failure. Eur J Anaesthesiol 2005; 22: 4-10
13. Sparr HJ, Vermeyen KM, Beaufort AM, et al. Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: Efficacy, safety, and pharmacokinetics. Anesthesiology 2007; 106: 935-43
14. Staals LM, Snoeck MM, Driessen JJ, Flockton EA, Heeringa M, Hunter JM. Multicentre, parallel-group, comparative trial evaluating the efficacy and safety of sugammadex in patients with endstage renal failure or normal renal function. Br J Anaesth 2008; 101: 492-7
15. Staals LM, Snoeck MM, Driessen JJ, et al. Reduced clearance of rocuronium and sugammadex in patients with severe to endstage renal failure: A pharmacokinetic study. Br J Anaesth 2010; 104: 31-9
16. Epemolu O, Mayer I, Hope F, Scullion P, Desmond P. Liquid chromatography/ mass spectrometric bioanalysis of a modified gamma-cyclodextrin (Org 25969) and rocuronium bromide (Org 9426) in guinea pig plasma and urine: Its application to determine the plasma pharmacokinetics of Org 25969. Rapid Commun Mass Spectrom 2002; 16: 1946-52
17. de Zwart MAH, ten Bruggencate-Broeders J, van Hal HJM, Megens HJJJ, Frasa WLH. Determination of sugammadex in human plasma, urine, and dialysate using a high-performance liquid chromatography/tandem mass spectrometry assay. J Chromatogr B Analyt Technol Biomed Life Sci 2011; 879: 1573-86
18. Marshall MR, Ma T, Galler D, Rankin AP, Williams AB. Sustained low-efficiency daily diafiltration (SLEDD-f) for critically ill patients requiring renal replacement therapy: Towards an adequate therapy. Nephrol Dial Transplant 2004; 19: 877-84
19. Vanholder R, Van Biesen W, Hoste E, Lameire N. Pro/con debate: Continuous versus intermittent dialysis for acute kidney injury:
20. Shearer ES, O'Sullivan EP, Hunter JM. Clearance of atracurium and laudanosine in the urine and by continuous venovenous haemofiltration. Br J Anaesth 1991; 67: 569-73
21. Dhonneur G, Rebaine C, Slavov V, Ruggier R, De Chaubry V, Duvaldestin P. Neostigmine reversal of vecuronium neuromuscular block and the influence of renal failure. AnesthAnalg 1996; 82: 134-8
22. Cronnelly R, Stanski DR, Miller RD, Sheiner LB, Sohn YJ. Renal function and the pharmacokinetics of neostigmine in anesthetized man. Anesthesiology 1979; 51: 222-6
23. Kirvelä M, Ali-Melkkilä T, Kaila T, Iisalo E, Lindgren L. Pharmacokinetics of glycopyrronium in uraemic patients. Br J Anaesth 1993; 71: 437-9
24. Flockton EA, Mastronardi P, Hunter JM, et al. Reversalof rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracuriuminduced block with neostigmine. Br J Anaesth 2008; 100: 622-30
25. Craig RG, Hunter JM. Neuromuscular blocking drugs and their antagonists in patients with organ disease. Anaesthesia 2009; 64 (Suppl. 1): 55-65
26. Sparr HJ, Wierda JM, Proost JH, Keller C, Khuenl-Brady KS. Pharmacodynamics and pharmacokinetics of rocuronium in intensive care patients. Br J Anaesth 1997; 78: 267-73
27. Dahl V, Pendeville PE, Hollmann MW, et al. Safety and efficacy of sugammadex for the reversal of rocuronium-induced neuromuscular blockade in cardiac patients undergoing noncardiac surgery. Eur J Anaesthesiol 2009; 26: 874-84
28. Yoshida F, Suzuki T, Kashiwai A, Furuya T, Konishi J, Ogawa S. Correlation between cardiac output and reversibility of rocuronium- induced moderate neuromuscular block with sugammadex. Acta Anaesthesiol Scand 2012; 56: 83-7